Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MARIA ANGELICA ABDALLA CORTEZ and JAMES WELSH.
MARIA ANGELICA ABDALLA CORTEZ
Connection Strength
11.828
JAMES WELSH
  1. Author Correction: Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun. 2020 Oct 08; 11(1):5144.
    View in: PubMed
    Score: 0.746
  2. Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun. 2020 09 24; 11(1):4840.
    View in: PubMed
    Score: 0.744
  3. In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. Mol Ther Nucleic Acids. 2015 Dec 15; 4:e270.
    View in: PubMed
    Score: 0.534
  4. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 2016 Jan; 108(1).
    View in: PubMed
    Score: 0.531
  5. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014 Aug; 22(8):1494-1503.
    View in: PubMed
    Score: 0.478
  6. Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapy. Front Oncol. 2024; 14:1407143.
    View in: PubMed
    Score: 0.246
  7. Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3. J Nanobiotechnology. 2024 Oct 01; 22(1):597.
    View in: PubMed
    Score: 0.246
  8. Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res. 2024 Sep 10; 43(1):256.
    View in: PubMed
    Score: 0.245
  9. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy. J Exp Clin Cancer Res. 2024 Mar 06; 43(1):70.
    View in: PubMed
    Score: 0.236
  10. Corrigendum: Lipid metabolism in tumor immunology and immunotherapy. Front Oncol. 2023; 13:1358498.
    View in: PubMed
    Score: 0.234
  11. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight. 2023 06 22; 8(12).
    View in: PubMed
    Score: 0.225
  12. NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model. Cancer Immunol Immunother. 2023 Sep; 72(9):3003-3012.
    View in: PubMed
    Score: 0.224
  13. Lipid metabolism in tumor immunology and immunotherapy. Front Oncol. 2023; 13:1187279.
    View in: PubMed
    Score: 0.223
  14. The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy. Front Immunol. 2023; 14:1172931.
    View in: PubMed
    Score: 0.222
  15. Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer. Cancer Immunol Res. 2023 04 03; 11(4):486-500.
    View in: PubMed
    Score: 0.221
  16. NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model. Res Sq. 2023 Feb 13.
    View in: PubMed
    Score: 0.219
  17. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Front Immunol. 2022; 13:1022011.
    View in: PubMed
    Score: 0.215
  18. Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance. Front Immunol. 2022; 13:1033642.
    View in: PubMed
    Score: 0.215
  19. Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Front Immunol. 2022; 13:984318.
    View in: PubMed
    Score: 0.214
  20. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. J Nanobiotechnology. 2022 Sep 19; 20(1):417.
    View in: PubMed
    Score: 0.213
  21. High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses. Cancers (Basel). 2022 Jan 03; 14(1).
    View in: PubMed
    Score: 0.203
  22. Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases. Front Immunol. 2021; 12:812210.
    View in: PubMed
    Score: 0.202
  23. Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. Front Oncol. 2021; 11:737425.
    View in: PubMed
    Score: 0.198
  24. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67.
    View in: PubMed
    Score: 0.196
  25. Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity. Transl Oncol. 2021 Feb; 14(2):100983.
    View in: PubMed
    Score: 0.189
  26. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches. Front Immunol. 2020; 11:573326.
    View in: PubMed
    Score: 0.187
  27. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.186
  28. Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):352-364.
    View in: PubMed
    Score: 0.184
  29. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. Radiother Oncol. 2020 09; 150:114-120.
    View in: PubMed
    Score: 0.182
  30. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.182
  31. SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020 07; 8(7):883-894.
    View in: PubMed
    Score: 0.180
  32. Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):196-203.
    View in: PubMed
    Score: 0.178
  33. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials. J Immunother Cancer. 2020 Jan; 8(1).
    View in: PubMed
    Score: 0.177
  34. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
    View in: PubMed
    Score: 0.175
  35. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses. Clin Cancer Res. 2019 12 15; 25(24):7576-7584.
    View in: PubMed
    Score: 0.173
  36. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer. 2019 09 04; 7(1):237.
    View in: PubMed
    Score: 0.173
  37. Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019 04; 58(4):244-253.
    View in: PubMed
    Score: 0.168
  38. IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):903-912.
    View in: PubMed
    Score: 0.167
  39. Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol Ther. 2019 03; 195:162-171.
    View in: PubMed
    Score: 0.163
  40. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects. Front Immunol. 2018; 9:2170.
    View in: PubMed
    Score: 0.162
  41. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. Clin Cancer Res. 2018 11 15; 24(22):5735-5743.
    View in: PubMed
    Score: 0.158
  42. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Lett. 2018 09 01; 431:54-63.
    View in: PubMed
    Score: 0.158
  43. Radiation and Anti-Cancer Vaccines: A Winning Combination. Vaccines (Basel). 2018 Jan 30; 6(1).
    View in: PubMed
    Score: 0.155
  44. Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res. 2017 Apr; 6(2):148-158.
    View in: PubMed
    Score: 0.146
  45. Optimizing Radiotherapy with Immunotherapeutic Approaches. Adv Exp Med Biol. 2017; 995:53-71.
    View in: PubMed
    Score: 0.144
  46. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850.
    View in: PubMed
    Score: 0.142
  47. Galectin-1 and immune suppression during radiotherapy. Clin Cancer Res. 2014 Dec 15; 20(24):6230-2.
    View in: PubMed
    Score: 0.123
  48. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8.
    View in: PubMed
    Score: 0.122
  49. Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer. 2013 May 15; 119(10):1768-75.
    View in: PubMed
    Score: 0.110
  50. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol. 2012 Aug; 7(8):1211-7.
    View in: PubMed
    Score: 0.106
  51. Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res. 2012; 195:151-61.
    View in: PubMed
    Score: 0.102
  52. Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res. 2024 Sep 02; 43(1):251.
    View in: PubMed
    Score: 0.061
  53. A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model. J Nanobiotechnology. 2021 Dec 11; 19(1):416.
    View in: PubMed
    Score: 0.051
  54. Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects. Int J Radiat Oncol Biol Phys. 2021 11 01; 111(3):647-657.
    View in: PubMed
    Score: 0.049
  55. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Front Immunol. 2019; 10:193.
    View in: PubMed
    Score: 0.042
  56. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res. 2018 04; 28(4):432-447.
    View in: PubMed
    Score: 0.039
  57. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J. 2016 Mar-Apr; 22(2):130-7.
    View in: PubMed
    Score: 0.034
  58. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct 28; 5:5241.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.